Alan Kaplan, Ph.D. Senior Director of CMC
Alan Kaplan, Ph.D.
Senior Director of CMC
Dr. Kaplan joined DNS as Director of Chemistry in 2003. He initially joined Helicon Therapeutics, which merged with DNS in 2012. While at Helicon, he was responsible for both the drug discovery and drug development activities in chemistry that led to 4 U.S. INDs. Since the merge with DNS, Dr. Kaplan has focused on drug development and CMC activities to move the DNS portfolio further into clinical development. Prior to joining DNS, Dr. Kaplan spent eight years at ArQule, Inc. in Woburn, MA, helping the company establish its high-throughput medicinal chemistry technologies. While at ArQule, Dr. Kaplan worked closely with their pharmaceutical and biotech partners on a number of drug discovery programs, eventually becoming Senior Director of Lead Optimization Chemistry. Dr. Kaplan pursued postdoctoral training at Harvard University after receiving his Ph.D. in 1991 from the University of California at Berkeley and a B.A. in 1986 from Northwestern University